Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laboratory-Treated T Cells and Ipilimumab in Metastatic Melanoma
NCT00871481Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2009
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Numeric frequency and functional persistence of transferred CTL and Toxicity assessment of study treatment. Started Feb 2009; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00871481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00871481.